Sharon Tetlow
Direktor/Vorstandsmitglied bei STRUCTURE THERAPEUTICS INC.
Vermögen: - $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Raymond Stevens | M | 60 |
Shanghai ShouTi Biotechnology Co., Ltd.
 Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin. | 5 Jahre |
| Jun Yoon | M | 46 |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin. | 5 Jahre |
| Shaan Gandhi | M | 38 |
DICE Molecules SV, Inc.
 DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 4 Jahre |
| Ramy Farid | M | 59 |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin. | 5 Jahre |
| Jake Simson | M | 38 |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 4 Jahre |
| Richard Scheller | M | 70 |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 9 Jahre |
| Stephen Zachary | M | 42 |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 5 Jahre |
| Jim Scopa | M | 65 |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 4 Jahre |
| Lance Thibault | M | 58 |
Danforth Advisors LLC
 Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | 10 Jahre |
| Peter Buhler | M | 54 | 3 Jahre | |
| Philip Johnson | M | 59 | 1 Jahre | |
| Xi Chen Lin | M | 50 |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin. | 5 Jahre |
| Vincent Dequenne | M | - | 3 Jahre | |
| Joanne Waldstreicher | M | 63 | 2 Jahre | |
| Jim Connolly | M | 59 | 2 Jahre | |
| Daniel Welch | M | 66 |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin. | 2 Jahre |
| Eric Dobmeier | M | 55 | 2 Jahre | |
| Ted Love | M | 65 | 1 Jahre | |
| Michael Thompson | M | - | 1 Jahre | |
| J. Judice | M | 61 |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | 11 Jahre |
| Jessica Lifton | F | - |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin. | - |
| Stephen DiPalma | M | 66 |
Danforth Advisors LLC
Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | 10 Jahre |
| Dipal Patel | F | - | 2 Jahre | |
| Tony Peng | M | - | - | |
| Gordon Brooks | M | - | 1 Jahre | |
| Ying Li Ma | M | 50 | 2 Jahre | |
| Lani Ibarra | F | - | - | |
| Mark Bach | M | 67 | 3 Jahre | |
| Juan Carlos Jaramillo | M | 53 | 4 Jahre | |
| Cui Ping Gu | M | 44 |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin. | - |
| Chen-Ming Yu | M | 50 |
Shanghai ShouTi Biotechnology Co., Ltd.
Shanghai ShouTi Biotechnology Co., Ltd. BiotechnologyHealth Technology Part of Structure Therapeutics, Inc., Shanghai ShouTi Biotechnology Co., Ltd. develops biotechnologies. The company is based in Shanghai, China. The CEO of the Chinese company is Xi Chen Lin. | - |
| Maïlys Ferrère | F | 60 | 2 Jahre | |
| William Romeo | M | - |
Danforth Advisors LLC
Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | 8 Jahre |
| Karen S. Wright | F | 69 | - | |
| Kathrin Jansen | M | - | 1 Jahre | |
| Chris Anderson | M | - | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Scott Robertson | M | 44 | 7 Jahre | |
| Seline E. Miller | F | 55 | 2 Jahre | |
| Deborah Neff | F | 71 |
Pathwork Diagnostics, Inc.
 Pathwork Diagnostics, Inc. Medical SpecialtiesHealth Technology Pathwork Diagnostics Inc. develops and delivers molecular diagnostics for oncology. The company was founded by Glenda Anderson, Richard Zare, and George M. Whitesides in 2003 and is headquartered in Redwood City, CA. | 9 Jahre |
| Alexander Ullrich von Gabain | M | 73 | 7 Jahre | |
| Stephen Sherwin | M | 75 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 19 Jahre |
| Edward Williams | M | 68 | 4 Jahre | |
| Sandra E. Poole | F | 60 | 3 Jahre | |
| Mittie Doyle | M | 59 | 1 Jahre | |
| Christine R. Boehning | F | 53 |
Danforth Advisors LLC
Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | 4 Jahre |
| Joseph J. Vallner | M | 76 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 Jahre |
| Lee Roy McCracken | M | 66 |
Pathwork Diagnostics, Inc.
Pathwork Diagnostics, Inc. Medical SpecialtiesHealth Technology Pathwork Diagnostics Inc. develops and delivers molecular diagnostics for oncology. The company was founded by Glenda Anderson, Richard Zare, and George M. Whitesides in 2003 and is headquartered in Redwood City, CA. | 1 Jahre |
| Andrew Hetherington | M | - | - | |
| William G. Gerber | M | 77 |
diaDexus, Inc. /Old/
 diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | 1 Jahre |
| Shiu Fei Ling | M | 67 | 2 Jahre | |
| Lisa Bowers | F | 51 | 1 Jahre | |
| Franck S. Rousseau | M | 67 | 1 Jahre | |
| Errol de Souza | M | 70 | 7 Jahre | |
| Steven James | M | 66 | 3 Jahre | |
| John Jacobsen | M | 56 | 8 Jahre | |
| Johanna Willemina Pattenier | M | 64 | 3 Jahre | |
| John J. Schembri | M | 62 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 3 Jahre |
| Klaus Schwamborn | M | - | 9 Jahre | |
| Timothy Lu | M | 49 | 3 Jahre | |
| Vivek Vyas | M | - |
Apax Partners, Inc.
 Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | - |
| Frédéric Grimaud | M | 59 | 11 Jahre | |
| Veronica Cai | F | 48 | 1 Jahre | |
| Ying Luo | M | 58 | - | |
| David Ian Issott | M | 47 |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | - |
| Linda Neuman | M | 59 | - | |
| Rob T. Davies | M | - |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | - |
| Jack Whalen | M | - |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | 2 Jahre |
| Thomas Eastling | M | 64 | - | |
| Amanda Hill | F | - | 15 Jahre | |
| Michael Byrnes | M | 47 | 3 Jahre | |
| Tom Knudsen | M | - | - | |
| Jeffrey Landau | M | 46 | 5 Jahre | |
| Tushar Maloo | M | - |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | - |
| Ori Sasson | M | - |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | 2 Jahre |
| Daniel Bonoff | M | - |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | - |
| Louis C. Bock | M | 59 |
diaDexus, Inc. /Old/
diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | 10 Jahre |
| Lori F. Rafield | M | 69 |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | 1 Jahre |
| Peter K. Working | M | 75 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 7 Jahre |
| John Apeler Keller | M | 60 |
diaDexus, Inc. /Old/
diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | 7 Jahre |
| David Landau | M | 57 |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | 1 Jahre |
| Kristen Hege | M | 60 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 12 Jahre |
| Eugene L. Step | M | 94 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 16 Jahre |
| John T. Potts | M | 92 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 12 Jahre |
| Inder Mohan Verma | M | 76 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 12 Jahre |
| George Poste | M | 79 |
diaDexus, Inc. /Old/
diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | 7 Jahre |
| Patrick Plewman | M | 58 |
diaDexus, Inc. /Old/
diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | 10 Jahre |
| Ronald M. Lindsay | M | 76 |
diaDexus, Inc. /Old/
diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | 4 Jahre |
| Robert L. Wolfert | M | 70 |
diaDexus, Inc. /Old/
diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | 10 Jahre |
| Darren Glatt | M | 48 |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | 2 Jahre |
| Eliot R. Charles | M | - |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | 1 Jahre |
| Esther Luh | F | - |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | 1 Jahre |
| Henry Nasella | M | 77 |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | 4 Jahre |
| Jeff Perlman | M | - |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | 5 Jahre |
| Johanna Epstein | F | - |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | 1 Jahre |
| Carol A. Olson | F | - |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | 1 Jahre |
| Manali Doshi | M | - |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | 1 Jahre |
| Sandeep Achyut Naik | M | 51 |
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | 8 Jahre |
| Greg Lahann | M | - |
Pathwork Diagnostics, Inc.
Pathwork Diagnostics, Inc. Medical SpecialtiesHealth Technology Pathwork Diagnostics Inc. develops and delivers molecular diagnostics for oncology. The company was founded by Glenda Anderson, Richard Zare, and George M. Whitesides in 2003 and is headquartered in Redwood City, CA. | 6 Jahre |
| C. Payne | M | 61 |
Pathwork Diagnostics, Inc.
Pathwork Diagnostics, Inc. Medical SpecialtiesHealth Technology Pathwork Diagnostics Inc. develops and delivers molecular diagnostics for oncology. The company was founded by Glenda Anderson, Richard Zare, and George M. Whitesides in 2003 and is headquartered in Redwood City, CA. | 3 Jahre |
| Philip Patten | M | - | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 85 | 85,00% |
| Frankreich | 12 | 12,00% |
| China | 8 | 8,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Sharon Tetlow
- Persönliches Netzwerk
